About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Cardiovascular Diseases group is a translational research group within the Cardiology Department of Vall d’Hebron Hospital that performs laboratory, clinical and epidemiological research. In the CIBERCV network we are within the topic of descriptor 2 “Arterial disease, thrombosis and myocardial ischemia-reperfusion injury”. Our contributions in these topics address the following lines:
In the CIBERESP network, our group is interested in the study of effectiveness/cost-effectiveness of cardiovascular interventions, health outcome research and methods in clinical research. The group has 19 principal investigators, 32 active projects and clinical trial and has been done 142 publications in 2020.
PMID: 33052376 Journal: JAMA Cardiology Year: 2021 Reference: JAMA Cardiol. 2021 Jan 1;6(1):58-66. doi: 10.1001/jamacardio.2020.4876. Impact factor: 14.676 Publication type: Paper in international publication Authors: Braverman, Alan C, Mittauer, Eric, Harris, Kevin M, Evangelista, Arturo, Pyeritz, Reed E, Brinster, Derek, Conklin, Lori, Suzuki, Toru, Fanola, Christina, Chen, Edward et al. DOI: 10.1001/jamacardio.2020.4876
PMID: 33404892 Journal: EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES Year: 2021 Reference: Eur J Clin Microbiol Infect Dis. 2021 Jun;40(6):1137-1148. doi: 10.1007/s10096-020-04117-x. Epub 2021 Jan 6. Impact factor: 3.267 Publication type: Paper in international publication Authors: Escola-Verge, Laura, Fernandez-Hidalgo, Nuria, Fernandez-Galera, Ruben, Almirante, Benito, Larrosa, Maria Nieves et al. DOI: 10.1007/s10096-020-04117-x
PMID: 33350866 Journal: Journal of the American Heart Association Year: 2021 Reference: J Am Heart Assoc. 2021 Jan 5;10(1):e018176. doi: 10.1161/JAHA.120.018176. Epub 2020 Dec 22. Impact factor: 5.501 Publication type: Paper in international publication Authors: Hasanova, I, Tutarel, Oktay, Ramlakhan, Karishma P, Baris, Lucia, Subirana, Maria T, Bouchardy, Judith, Nemes, Attila, Vejlstrup, Niels G, Osipova, Olga A, Johnson, Mark R et al. DOI: 10.1161/JAHA.120.018176
PMID: 33399006 Journal: Journal of the American Heart Association Year: 2021 Reference: J Am Heart Assoc. 2021 Jan 19;10(2):e019949. doi: 10.1161/JAHA.120.019949. Epub 2021 Jan 5. Impact factor: 5.501 Publication type: Paper in international publication Authors: Alonso-Gomez, Angel, Botas, Javier, Crespo-Leiro, Maria G, Velasco, Sonia, Bayes-Genis, Antoni, Lopez, Amador, Munoz-Aguilera, Roberto, Jimenez-Navarro, Manuel, Gonzalez-Juanatey, Jose R, Evangelista, Arturo et al. DOI: 10.1161/JAHA.120.019949
The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.
In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.
The Cardiovascular Diseases and Neurovascular Diseases groups at VHIR will investigate new therapeutic strategies for heart failure, nanomedicine in stroke and the prevention of cardiovascular toxicity in the case of oncological treatments.
